OPU
AUPH icon

Omni Partners US’s Aurinia Pharmaceuticals AUPH Stock Holding History

Omni Partners US’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.62M Buy
+73,290
New +$1.16M 0.08% 164

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Omni Partners US's AUPH Position: Q3 2021 in Review

Omni Partners US opened a new position in Aurinia Pharmaceuticals (AUPH) in Q3 2021: 73,290 shares worth $1.62M. The stake represents 0.08% of the portfolio and ranks #164 among its holdings.

166 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

  • Omni Partners US held 73,290 shares of Aurinia Pharmaceuticals worth $1.62M as of Q3 2021.
  • Aurinia Pharmaceuticals was a new Omni Partners US position in Q3 2021.
  • Aurinia Pharmaceuticals made up 0.08% of Omni Partners US's portfolio in Q3 2021, its #164 holding.
  • 166 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.